Research programme: corticotropin releasing factor receptor antagonists - Neurocrine/GlaxoSmithKline

Drug Profile

Research programme: corticotropin releasing factor receptor antagonists - Neurocrine/GlaxoSmithKline

Alternative Names: NBI-35583; NBI-35965

Latest Information Update: 24 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neurocrine Biosciences
  • Developer GlaxoSmithKline; Neurocrine Biosciences
  • Class Small molecules
  • Mechanism of Action Corticotropin releasing factor receptor 1 antagonists; Corticotropin releasing factor receptor 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anxiety disorders; Irritable bowel syndrome; Major depressive disorder

Most Recent Events

  • 19 Sep 2005 Data presented at the 230th American Chemical Society National Meeting (230th-ACS-2005) have been added to the Anxiety disorders pharmacodynamics section
  • 19 May 2005 A preclinical study has been added to the Anxiety disorders pharmacodynamics section
  • 12 Aug 2003 Preclinical trials in Anxiety disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top